| 发明名称 |
COMBINATION THERAPY FOR PD-L1 NEGATIVE TUMORS |
| 摘要 |
The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and tremelimumab in a subject identified as having a PD-L1 negative tumor. |
| 申请公布号 |
US2016060344(A1) |
申请公布日期 |
2016.03.03 |
| 申请号 |
US201514838650 |
申请日期 |
2015.08.28 |
| 申请人 |
Narwal Rajesh;Rebelatto Marlon C.;Steele Keith;Robbins Paul;Stewart Ross Anthony;Blake-Haskins John A.;Karakunnel Joyson J.;Ibrahim Ramy;Shalabi Aiman;Di Pietro Alessandra;Shi Li;Hong Shengyan;Stockman Paul;Ballas Marc;Dar Mohammed M. |
发明人 |
Narwal Rajesh;Rebelatto Marlon C.;Steele Keith;Robbins Paul;Stewart Ross Anthony;Blake-Haskins John A.;Karakunnel Joyson J.;Ibrahim Ramy;Shalabi Aiman;Di Pietro Alessandra;Shi Li;Hong Shengyan;Stockman Paul;Ballas Marc;Dar Mohammed M. |
| 分类号 |
C07K16/28 |
主分类号 |
C07K16/28 |
| 代理机构 |
|
代理人 |
|
| 主权项 |
1. A method of treatment comprising administering an anti-PD-L1 antibody and an anti-CTLA4 antibody, or antigen binding fragments thereof, to a patient identified as having a lung cancer that is negative for PD-L1. |
| 地址 |
Gaithersburg MD US |
